Inhibits DNA-dependent Independent protein kinase, ataxia teleangectasia mutated Strogenrezeptor, mTOR, and even spannungsabh Ngigen K-Kan Le. Therefore, k Can some of the effects of LY294002 do not directly on his F Standing ability to inhibit PI3K.

Wortmannin is a fungicide, which was originally isolated from the soil and is an irreversible inhibitor Danoprevir ITMN-191 of PI3K. Treatment with lower phospho Akt in wortmannin PC 3 and LNCaP cells, and induces apoptosis and radiosensitized DU 145 cells. Wortmannin, Similar to LY294002, is not specific to PI3K and inhibits several other signaling molecules. Unfortunately, the use of both in vivo, LY294002 and wortmannin, have faced significant negative side effects. However, in vivo, LY294002 decreased phosphorylation and protein eIF4F ofdownstream Translation in the prostate of transgenic M Mice, a constitutively active catalytic subunit of PI3K.
, And increased Were detected hte levels of phosphorylated Akt in primary Rtumoren of patients Close Lich experienced PSA recurrence w was found while no correlation between the expression of Akt and biochemical relapse. In addition, increased Were brought hte phosphorylated Regorafenib Raf inhibitor Akt be detected in the tissues compared to tissues of hormone-sensitive and have CRPC with disease-free survival in combination reduced specific. Results of a study to evaluate the expression of Akt isoforms in relation to the recurrence of prostate cancer showed that only a high cytoplasmic act combined with a low nuclear act independently Ngig predicted time to biochemical failure.
Levels of mTOR and phospho DAPT mTOR cytoplasmic were h Forth in prostate cancer tissue compared to normal prostate epithelium, with levels of mTOR in cancer cells twice that of benign tissue. Phospho MTOR was detected in small amounts in the cytoplasm and at moderate to high levels along the membrane in the epithelium of normal prostate, w While strong in cancer cells Immunreaktivit t evidence of mTOR phospho both the membrane and the cytoplasm. A comparison of the values of downstream signaling molecules Rts of mTOR, S6 and 4E BP1, also showed h Here in prostate cancer compared to normal cells. Further evidence for the activity T of mTOR in prostate cancer is indirect and comes from the use of mTOR inhibitors, which are discussed below. The inhibition of the PI3K/Akt/mTOR prostate PI3K inhibition of various small molecule inhibitors of the PI3K/Akt path investigated / mTOR were both in vitro and in vivo prostate cancer.
Inhibitors of PI3K, the most studied so far are LY294002 and wortmannin. LY294002 is a potent and competitive antagonist of PI3K. LY294002 treatment has finished Born a cell cycle arrest of LNCaP cells and sensitizes these cells to radiation inhibited, a decrease of invasive properties of cells, LNCaP, PC-3 and DU-145 cells, and angiogenesis in PC3 cells via an RESTRICTIONS LIMITATION of HIF1 and VEGF . LY294002 also lowered the level of phospho Akt in PC-3 and LNCaP cells. However, additionally Tzlich to inhibition of PI3K, LY294002 inhibits DNA-dependent Independent protein kinase, ataxia teleangectasia mutated Strogenrezeptor, mTOR, and even spannungsabh Ngigen K-Kan Le. Therefore, k Can some of the effects of LY294002 do not directly on his F Standing ability to inhibit PI3K. Wortmannin is a fungicide, which was originally isolated from the soil and is an irreversible inhibitor